Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial Studying 767 children ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...

Findings showed 42% of pediatric patients (22/53) achieved complete remission. The Food and Drug Administration (FDA) has approved Besponsa (inotuzumab ozogamicin) for the treatment of relapsed or ...

In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred Hutch Cancer Center ...

CAR T-cell therapy on the National Health Service offers adults with fast-moving B-cell leukemia years of life, fewer side ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion ...

Evaluation of the toxicity and outcomes of the combination of midostaurin and CLAG-M in patients with FLT3-mutated acute myeloid leukemia (AML): A multi-center retrospective analysis. This is an ASCO ...